SequelSEC

PLIANT THERAPEUTICS, INC. PLRX

Pharmaceutical Preparations · CIK 0001746473 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PLIANT THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PLIANT THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
RevenueUnavailable$0$0$0$0$0$0$248.00K$1.33M$1.96M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailable-$53.32M-$62.01M-$60.64M-$52.39M-$47.04M-$47.68M-$47.33M-$42.10M-$37.40M
Net incomeUnavailable-$49.73M-$57.76M-$55.85M-$46.96M-$41.11M-$41.49M-$41.19M-$37.55M-$35.06M
Research & developmentUnavailable$38.79M$47.75M$45.62M$37.15M$33.18M$32.34M$33.00M$29.27M$25.11M
Weighted-average diluted sharesUnavailableUnavailableshares 60.73Mshares 60.38Mshares 60.18MUnavailableshares 59.69Mshares 59.17Mshares 56.06MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailable$-0.95$-0.92$-0.78Unavailable$-0.70$-0.70$-0.67Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$14.53M$14.26M$15.02M$15.25M$13.85M$15.35M$14.57M$14.15M$14.25M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PLIANT THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Cash & equivalents$45.44M$71.19M$79.62M$80.39M$114.30M$63.23M$57.68M$54.95M$102.53M$33.68M
Total assets$225.23M$396.95M$445.66M$483.73M$521.60M$512.15M$540.46M$574.89M$597.88M$350.61M
Current assets$196.45M$362.26M$410.03M$447.55M$489.90M$505.50M$534.34M$565.70M$588.23M$340.31M
Total liabilities$44.02M$92.87M$99.84M$91.05M$84.27M$38.58M$37.42M$41.83M$35.96M$37.27M
Current liabilities$16.36M$33.22M$39.95M$30.92M$30.39M$28.52M$27.40M$29.52M$23.15M$23.91M
Total equity incl. NCI$181.20M$304.08M$345.82M$392.68M$437.33M$473.58M$503.05M$533.06M$561.92M$313.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$1.58M$3.30M$1.98M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$30.21M$30.14M$30.07M$30.00M$10.05M$10.02M$9.99M$9.96M$9.93M
Accounts payable$480.00K$5.96M$6.89M$3.25M$7.33M$4.53M$3.36M$2.31M$1.42M$1.58M

Cash flow

PLIANT THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Operating cash flowUnavailable-$47.66M-$32.27M-$45.30M-$30.27M-$25.10M-$36.22M-$24.76M-$30.28M-$31.24M
Capital expendituresUnavailable$209.00K$896.00K$1.25M$1.49M$61.00K$94.00K$603.00K$163.00K$166.00K
Investing cash flowUnavailable$39.13M$30.96M$10.70M$59.55M$31.92M$38.25M-$22.98M-$174.21M$20.02M
Financing cash flowUnavailable$102.00K$543.00K$684.00K$21.79M$219.00K$699.00K$161.00K$273.33M$284.00K
Net change in cashUnavailable-$8.43M-$770.00K-$33.91M$51.06M$7.04M$2.73M-$47.58M$68.84M-$10.93M
Stock-based compensationUnavailable$8.42M$8.90M$10.64M$9.67M$9.15M$10.36M$13.05M$11.92M$10.86M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PLIANT THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Free cash flowUnavailable-$47.87M-$33.17M-$46.55M-$31.76M-$25.16M-$36.32M-$25.36M-$30.44M-$31.40M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-19083.9%-3160.3%-1903.3%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-10226.6%-2285.2%-1598.2%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable5260.5%895.1%552.4%
Current ratio12.00x10.91x10.26x14.47x16.12x17.72x19.50x19.16x25.41x14.23x
Revenue YoY growthUnavailableUnavailableUnavailable-100.0%-100.0%-100.0%-100.0%-95.0%6.6%-1.7%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-1784.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable13307.3%2197.7%1278.1%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable243.1%12.2%8.4%
Long-term debt / equity0.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.